# Cellectis (CLLS) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/CLLS
## Company Profile
- Ticker: CLLS
- Exchange: NASDAQ
- Sector: Biopharma
- Location: France
- Tags: Oncology
## Stock Data
- Close: 2.89 USD
- Market cap: 340066805.78 USD
- Last updated: 2026-08-11
## Business Overview
### Gene-Edited Allogeneic Cell Therapy
Cellectis develops off-the-shelf CAR T-cell therapies using TALEN gene editing and related genome-engineering technologies.
### UCART Platform
The platform modifies healthy donor T cells to add tumor targeting and reduce immune incompatibility, enabling standardized inventory-based treatment.
### BALLI-01
The pivotal Phase 2 BALLI-01 study evaluates a Cellectis allogeneic CAR T therapy in relapsed or refractory B-cell acute lymphoblastic leukemia.
### Partnered Programs
Cellectis retains economic and technology exposure to partnered products including cema-cel, originally developed as UCART19 and advanced by Allogene and Servier.
### TALE Epigenetic Editing
Beyond DNA-cutting applications, Cellectis is developing TALE-based epigenetic editing to regulate gene activity without creating double-strand DNA breaks.
## Why The Stock Is Moving

As of Aug 11, 2026, CLLS closed up 4.71% at $2.89. No new same-company headline was identified in the current news window.

## Future Catalysts

- The first interim analysis from the pivotal Phase 2 BALLI-01 study is expected in the fourth quarter of 2026.
- Study accrual is expected to complete by year-end 2027, with an interim event-free survival analysis in mid-2027 and primary analysis in mid-2028.
- Cellectis anticipates a BLA submission in 2028.

## Drug Assets

- cema-cel

## Recent News
- 2026-08-06 20:30 EST — [Cellectis Reports Financial Results for the Second Quarter 2026](https://biopharmsignal.com/news/CLLS/cellectis-reports-financial-results-for-the-second-quarter-2026-b233bf32) — Source: Cellectis
- 2026-07-30 20:30 EST — [Cellectis to Report Second Quarter Financial Results on August 6, 2026](https://biopharmsignal.com/news/CLLS/cellectis-to-report-second-quarter-financial-results-on-august-6-2026-9a15aa1c) — Source: Cellectis
- 2026-06-25 20:30 EST — [Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026](https://biopharmsignal.com/news/CLLS/cellectis-reports-results-from-shareholders-meeting-held-on-june-25-2026-28c487bb) — Source: Cellectis
- 2026-06-11 06:40 EST — [Cellectis Presents Final Phase 1 Results of Lasme-cel and  Preliminary Results on Eti-cel at EHA 2026 Congress](https://biopharmsignal.com/news/CLLS/cellectis-presents-final-phase-1-results-of-lasme-cel-and-preliminary-results-on-ea9f9ebc) — Source: Cellectis
- 2026-06-09 20:30 EST — [Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL](https://biopharmsignal.com/news/CLLS/cellectis-receives-fda-rmat-designation-for-lasme-cel-the-first-allogeneic-car-t-629c5c17) — Source: Cellectis